Literature DB >> 28382308

A novel mutation in KIF5A in a Malian family with spastic paraplegia and sensory loss.

Cheick O Guinto1, Salimata Diarra1, Salimata Diallo2, Lassana Cissé1, Thomas Coulibaly1, Seybou H Diallo2, Abdoulaye Taméga1, Ke-Lian Chen3, Alice B Schindler3, Koumba Bagayoko1, Assiatou Simaga4, Craig Blackstone3, Kenneth H Fischbeck3, Guida Landouré5.   

Abstract

Hereditary spastic paraplegias (HSPs) are well-characterized disorders but rarely reported in Africa. We evaluated a Malian family in which three individuals had HSP and distal muscle atrophy and sensory loss. HSP panel testing identified a novel heterozygous missense mutation in KIF5A (c.1086G>C, p.Lys362Asn) that segregated with the disease (SPG10). Lys362 is highly conserved across species and Lys362Asn is predicted to be damaging. This study shows that HSPs are present in sub-Saharan Africa, although likely underdiagnosed. Increasing efficiency and decreasing costs of DNA sequencing will make it more feasible to diagnose HSPs in developing countries.

Entities:  

Year:  2017        PMID: 28382308      PMCID: PMC5376762          DOI: 10.1002/acn3.402

Source DB:  PubMed          Journal:  Ann Clin Transl Neurol        ISSN: 2328-9503            Impact factor:   4.511


Introduction

Hereditary spastic paraplegias (HSPs) are clinically and genetically heterogeneous neurologic disorders that manifest with progressive lower extremity hypertonia and hyperreflexia along with typically more mild lower limb weakness in “pure” forms and with other associated neurologic or non‐neurologic symptoms in “complicated” (or “complex”) forms.1 HSP is often due to a progressive, length‐dependent degeneration of the corticospinal tracts and posterior columns of the spinal cord, though abnormal development may play a role as well. All modes of inheritance are seen, and the clinical presentations can show striking inter‐ and intra‐family variability. While dominant HSPs are prevalent in northern Europe and North America, recessive cases are mostly seen in North Africa, the Middle East, and Mediterranean regions.1, 2, 3 Although prevalent in other populations, genetically confirmed HSP cases in sub‐Saharan Africa in general, and West Africa in particular, are rare.4 Here, we report here a novel mutation in an HSP gene in a previously unstudied population in Mali.

Methods

All patients were evaluated by a group of neurologists after giving informed consent. Brain MRI plus HTLV‐1 and HIV serologies were performed to exclude common causes of spasticity in this population. Nerve conduction studies (NCS) and ophthalmologic examinations were performed to assess peripheral nerve or ocular involvement. DNA was extracted from peripheral blood in all available family members for genetic analysis. Next‐generation DNA sequencing assessing 58 HSP genes was performed commercially (Medical Neurogenetics, Atlanta, GA). DNA from all available family members was sequenced for segregation analyses.

Results

The index subject, of Khasonka ethnicity, was admitted for an ischemic stroke of the right superficial Sylvian artery that caused weakness in his left limbs. During examination, upper motor neuron signs were noticed on the right side as well. Further investigation revealed that he had experienced problems with walking at around 20 years of age, and two of his sons had the same symptoms. Other family members were subsequently evaluated. The disease distribution within the family was consistent with autosomal dominant inheritance (Fig. 1).
Figure 1

Pedigree of the family showing the autosomal dominant inheritance pattern. Individuals with Hereditary spastic paraplegias (HSP) phenotype (solid black) and individuals with SCA (solid gray) are indicated. The arrow identifies the proband. Ages at examination are shown at the top of each symbol, and asterisks (*) identify those seen in clinic.

Pedigree of the family showing the autosomal dominant inheritance pattern. Individuals with Hereditary spastic paraplegias (HSP) phenotype (solid black) and individuals with SCA (solid gray) are indicated. The arrow identifies the proband. Ages at examination are shown at the top of each symbol, and asterisks (*) identify those seen in clinic. Three subjects were found to be affected based on clinical examination, with spastic gait, extensor plantar responses, and brisk reflexes in all those affected (Table 1). There were no visual or hearing complaints, but the eldest patient had dysarthria, possibly due to his concurrent stroke. In addition, patients had muscle atrophy and weakness in lower extremities along with decreased pin‐prick and vibration sense. NCS showed slightly decreased conduction velocities in both tibial nerves at 39 m/sec with increased F‐wave latency at 63.5 msec in the 23‐year‐old patient (shown in italic in Table 1). The youngest patient also had an increased F‐wave latency. SPG4 deletion and duplication testing was negative, and targeted HSP next‐generation sequencing of one affected individual identified a heterozygous missense variant in the KIF5A gene at position c.1086G>C (Fig. 2A and B), leading to the amino acid change p.Lys362Asn. The Lys362 residue is located in a highly conserved, Lys‐rich domain of the protein (Fig. 2C), and mutation in the neighboring Ala361 residue has been reported in autosomal dominant “pure” SPG10.
Table 1

Phenotypic characteristics of subjects with SPG10

PatientClinical and demographic featuresNerve conduction studies
Age (year)SexAge of onset (year)First symptomSpasticityDistal leg weakness and atrophySensory lossLeft medianSuralPeronealTibial
RightLeftRightLeft
CMAP Amp (mV)CV m/secSNAP AmpCMAP Amp (mV)CV m/secCMAP Amp (mV)CV m/secF wave (msec)CMAP Amp (mV)CV m/secCMAP Amp (mV)CV m/secF wave (msec)
III.368M~20Walking difficultyYesModerateModerateNDNDNDNDNDNDNDNDNDNDNDNDND
IV.923M10Walking difficultyYesModerateModerate17.557269.745946 59 5.2 39 6.4 39 63.5
IV.1021M11Walking difficultyYesMildMild12.16029154613.7475210.24311.444 58

Amp, amplitude; SNAP, sensory nerve action potential; CMAP, compound motor action potential; ND, not done; CV, conduction velocity, normal median CMAP>4.5 mV (recorded at abductor pollicis brevis muscle), normal peroneal CMAP>2.5 mV (recorded at extensor digitorus brevis muscle), normal tibial CMAP>6 mV (recorded at abductor hallucis muscle), normal sural SNAP>10 μV, normal F wave<55 msec.

Figure 2

Electropherograms of the novel sequence variant. Sanger DNA sequencing shows an unaffected family member to be homozygous (G/G; panel A), while the affected individual is heterozygous (G/C), for the pathogenic variant (denoted by *; panel B). Protein sequence alignment of in various species (amino acid numbers refer to the human sequence). The SPG10 mutation causes an amino acid change at Lys362, a highly conserved residue (in red, asterisk above, panel C).

Phenotypic characteristics of subjects with SPG10 Amp, amplitude; SNAP, sensory nerve action potential; CMAP, compound motor action potential; ND, not done; CV, conduction velocity, normal median CMAP>4.5 mV (recorded at abductor pollicis brevis muscle), normal peroneal CMAP>2.5 mV (recorded at extensor digitorus brevis muscle), normal tibial CMAP>6 mV (recorded at abductor hallucis muscle), normal sural SNAP>10 μV, normal F wave<55 msec. Electropherograms of the novel sequence variant. Sanger DNA sequencing shows an unaffected family member to be homozygous (G/G; panel A), while the affected individual is heterozygous (G/C), for the pathogenic variant (denoted by *; panel B). Protein sequence alignment of in various species (amino acid numbers refer to the human sequence). The SPG10 mutation causes an amino acid change at Lys362, a highly conserved residue (in red, asterisk above, panel C). The p.Lys362Asn substitution of a positively charged with an uncharged amino acid is predicted to be damaging by an in silico method (Mutation Taster). Sequencing of DNA from eight other family members demonstrated that the Lys362Asn mutation co‐segregates perfectly with disease status, and this variant was not seen in various SNP databases (ExAC Browser: 0.00000, dbSNP, 1000genome). Another branch of the family (individual II.4 and relatives) had a genetically confirmed spinocerebellar ataxia (SCA2) characterized by ataxia and slurred speech.

Discussion

More than 90 HSP‐related genes (SPG1‐78, plus others) have been reported worldwide, and mutations in about 60 identified genes have been associated with these clinical variants.5 However, reports of genetically confirmed HSPs in the African population are scant and involve a limited number of these genes, mostly recessive forms.6 In Africa, a majority of spinal disorders appears due to injury or other known causes such as infectious or tumor,7 but genetic forms are likely underdiagnosed because of the cost and limited availability of genetic testing. Mutations in KIF5A have been associated with both HSP (SPG10) and CMT2.8 Previous reports of autosomal dominant HSP caused by KIF5A mutations have shown a clinical variability within and between families, but complicated cases are more frequent, especially in some populations.9 In addition to spasticity, some patients have peripheral neuropathy manifesting with muscle atrophy and weakness, and sensory loss in extremities.8 Furthermore, a small number of cases are characterized by infantile onset with myoclonus, hypotonia, optic nerve abnormalities, dysphagia, and apnea.10 To our knowledge, mutation in KIF5A has not been previously reported in Africa. In the family we describe here, the age of onset ranged from about 14–40 years, with a wide range of clinical variability. KIF5A encodes a member of the kinesin family of proteins that has three structural domains.11 The mutated residue described here is located in the coiled coil domain and is conserved across species from mammals to fruit flies. Although dominant HSPs are the most prevalent HSPs worldwide, in Africa (and in North Africa in particular where most HSP cases have been reported), recessive cases predominate. This is likely due to the high rate of consanguinity in these populations. KIF5A mutations have been reported in Asia, Europe and North America,12, 13, 14 but no cases have been reported in Africa, probably due to much more limited access to genetic testing. In summary, our study has identified a novel, autosomal dominant missense mutation in the KIF5A gene in a Malian family, broadening the genetic heterogeneity of HSPs in the African population and expanding the geographic spectrum of SPG10. Larger cohort studies in Africa will likely uncover many new HSP cases, representing new genes as well as known genes with mutations described in other populations.

Conflict of Interest

The authors declare no conflict of interest.
  14 in total

Review 1.  Hereditary spastic paraplegias.

Authors:  A E Harding
Journal:  Semin Neurol       Date:  1993-12       Impact factor: 3.420

2.  Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation in C19orf12.

Authors:  Guida Landouré; Peng-Peng Zhu; Charles M Lourenço; Janel O Johnson; Camilo Toro; Katherine V Bricceno; Carlo Rinaldi; Katherine G Meilleur; Modibo Sangaré; Oumarou Diallo; Tyler M Pierson; Hiroyuki Ishiura; Shoji Tsuji; Nichole Hein; John K Fink; Marion Stoll; Garth Nicholson; Michael A Gonzalez; Fiorella Speziani; Alexandra Dürr; Giovanni Stevanin; Leslie G Biesecker; John Accardi; Dennis M D Landis; William A Gahl; Bryan J Traynor; Wilson Marques; Stephan Züchner; Craig Blackstone; Kenneth H Fischbeck; Barrington G Burnett
Journal:  Hum Mutat       Date:  2013-08-12       Impact factor: 4.878

3.  A novel mutation in motor domain of KIF5A associated with an HSP/axonal neuropathy phenotype.

Authors:  Fabrizio Rinaldi; Maria T Bassi; Alice Todeschini; Silvia Rota; Alessia Arnoldi; Alessandro Padovani; Massimiliano Filosto
Journal:  J Clin Neuromuscul Dis       Date:  2015-03

4.  Hereditary ataxias and spastic paraplegias: methodological aspects of a prevalence study in Portugal.

Authors:  M C Silva; P Coutinho; C D Pinheiro; J M Neves; P Serrano
Journal:  J Clin Epidemiol       Date:  1997-12       Impact factor: 6.437

5.  KIF5A mutations cause an infantile onset phenotype including severe myoclonus with evidence of mitochondrial dysfunction.

Authors:  Jessica Duis; Shannon Dean; Carolyn Applegate; Amy Harper; Rui Xiao; Weimin He; James D Dollar; Lisa R Sun; Marta Biderman Waberski; Thomas O Crawford; Ada Hamosh; Carl E Stafstrom
Journal:  Ann Neurol       Date:  2016-08-24       Impact factor: 10.422

Review 6.  Tropical myelopathies.

Authors:  Gustavo C Román
Journal:  Handb Clin Neurol       Date:  2014

7.  Complicated forms of autosomal dominant hereditary spastic paraplegia are frequent in SPG10.

Authors:  Cyril Goizet; Amir Boukhris; Emeline Mundwiller; Chantal Tallaksen; Sylvie Forlani; Annick Toutain; Nathalie Carriere; Véronique Paquis; Christel Depienne; Alexandra Durr; Giovanni Stevanin; Alexis Brice
Journal:  Hum Mutat       Date:  2009-02       Impact factor: 4.878

8.  A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10).

Authors:  Evan Reid; Mark Kloos; Allison Ashley-Koch; Lori Hughes; Simon Bevan; Ingrid K Svenson; Felicia Lennon Graham; Perry C Gaskell; Andrew Dearlove; Margaret A Pericak-Vance; David C Rubinsztein; Douglas A Marchuk
Journal:  Am J Hum Genet       Date:  2002-09-24       Impact factor: 11.025

9.  Tunisian hereditary spastic paraplegias: clinical variability supported by genetic heterogeneity.

Authors:  A Boukhris; G Stevanin; I Feki; P Denora; N Elleuch; M I Miladi; C Goizet; J Truchetto; S Belal; A Brice; C Mhiri
Journal:  Clin Genet       Date:  2009-05-05       Impact factor: 4.438

10.  Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study.

Authors:  Anne Kjersti Erichsen; Jeanette Koht; Asbjørg Stray-Pedersen; Michael Abdelnoor; Chantal M E Tallaksen
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  8 in total

1.  Hereditary spastic paraplegia type 35 in a family from Mali.

Authors:  Guida Landouré; Kékouta Dembélé; Lassana Cissé; Oumar Samassékou; Salimata Diarra; Abdoulaye Bocoum; Mohamede E Dembélé; Kenneth H Fischbeck; Cheick O Guinto
Journal:  Am J Med Genet A       Date:  2019-05-14       Impact factor: 2.802

2.  [Clinical and laboratory features of recessive Limb Girdle Muscular dystrophies in the Department Neurology of University Hospital of Point G].

Authors:  Th Coulibaly; A J Ouabo; G Landouré; H O Bah; L Cissé; S H Diallo; S Diallo; O Samassékou; A B Maïga; F Kané; A Yalcouyé; A Taméga; A Bocoum; M E Dembélé; A Témé; C O Sidibé; A K Cissé; O Traoré; M Traoré; C O Guinto
Journal:  Health Sci Dis       Date:  2021-11

3.  A novel variant in the spatacsin gene causing SPG11 in a Malian family.

Authors:  Guida Landouré; Kékouta Dembélé; Salimata Diarra; Lassana Cissé; Oumar Samassékou; Abdoulaye Bocoum; Abdoulaye Yalcouyé; Moussa Traoré; Kenneth H Fischbeck; Cheick O Guinto
Journal:  J Neurol Sci       Date:  2020-01-07       Impact factor: 3.181

Review 4.  Disrupted neuronal trafficking in amyotrophic lateral sclerosis.

Authors:  Katja Burk; R Jeroen Pasterkamp
Journal:  Acta Neuropathol       Date:  2019-02-05       Impact factor: 17.088

5.  Hot-spot KIF5A mutations cause familial ALS.

Authors:  David Brenner; Rüstem Yilmaz; Kathrin Müller; Torsten Grehl; Susanne Petri; Thomas Meyer; Julian Grosskreutz; Patrick Weydt; Wolfgang Ruf; Christoph Neuwirth; Markus Weber; Susana Pinto; Kristl G Claeys; Berthold Schrank; Berit Jordan; Antje Knehr; Kornelia Günther; Annemarie Hübers; Daniel Zeller; Christian Kubisch; Sibylle Jablonka; Michael Sendtner; Thomas Klopstock; Mamede de Carvalho; Anne Sperfeld; Guntram Borck; Alexander E Volk; Johannes Dorst; Joachim Weis; Markus Otto; Joachim Schuster; Kelly Del Tredici; Heiko Braak; Karin M Danzer; Axel Freischmidt; Thomas Meitinger; Tim M Strom; Albert C Ludolph; Peter M Andersen; Jochen H Weishaupt
Journal:  Brain       Date:  2018-03-01       Impact factor: 13.501

6.  A novel KIF5A gene variant causes spastic paraplegia and cerebellar ataxia.

Authors:  Yusen Qiu; Shanshan Zhong; Lu Cong; Ling Xin; Xuguang Gao; Jun Zhang; Daojun Hong
Journal:  Ann Clin Transl Neurol       Date:  2018-09-17       Impact factor: 4.511

7.  Disruption of genes associated with Charcot-Marie-Tooth type 2 lead to common behavioural, cellular and molecular defects in Caenorhabditis elegans.

Authors:  Ming S Soh; Xinran Cheng; Tarika Vijayaraghavan; Arwen Vernon; Jie Liu; Brent Neumann
Journal:  PLoS One       Date:  2020-04-15       Impact factor: 3.240

Review 8.  A review of the genetic spectrum of hereditary spastic paraplegias, inherited neuropathies and spinal muscular atrophies in Africans.

Authors:  Amokelani C Mahungu; Nomakhosazana Monnakgotla; Melissa Nel; Jeannine M Heckmann
Journal:  Orphanet J Rare Dis       Date:  2022-03-24       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.